Alkermes Earnings: Everything You Must Know Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Alkermes, Inc. (NASDAQ:ALKS) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Alkermes, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $0.40 in the quarter versus EPS of $-0.13 in the year-earlier quarter.

Revenue: Rose 25.24% to $163.4 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Alkermes, Inc. reported adjusted EPS income of $0.40 per share. By that measure, the company beat the mean analyst estimate of $0.17. It beat the average revenue estimate of $128.01 million.

Quoting Management: “Our financial results reported today reflect the financial transformation of Alkermes. Our business is now evolving to the next stage as our pipeline of highly differentiated candidates advances and demonstrates its blockbuster potential,” commented Richard Pops, Chief Executive Officer of Alkermes. “Our recent pipeline progress validates Alkermes’ strategy to identify and develop new medicines that address critical unmet needs for patients suffering from major chronic CNS diseases. This year marks a significant inflection point for Alkermes as our clinical candidates advance across all stages of the pipeline.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business